MetLife Investment Management’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-33,135
| Closed | -$1.71M | – | 2870 |
|
|
2022
Q3 | $1.71M | Buy |
33,135
+519
| +2% | +$21.5K | 0.01% | 944 |
|
|
2022
Q2 | $808K | Buy |
32,616
+2,096
| +7% | +$46.2K | 0.01% | 1328 |
|
|
2022
Q1 | $765K | Buy |
30,520
+11,331
| +59% | +$318K | 0.01% | 1497 |
|
|
2021
Q4 | $699K | Hold |
19,189
| – | – | 0.01% | 1308 |
|
|
2021
Q3 | $328K | Hold |
19,189
| – | – | ﹤0.01% | 1770 |
|
|
2021
Q2 | $257K | Hold |
19,189
| – | – | ﹤0.01% | 1996 |
|
|
2021
Q1 | $983K | Sell |
19,189
-1,763
| -8% | -$106K | 0.01% | 1166 |
|
|
2020
Q4 | $1.3M | Hold |
20,952
| – | – | 0.01% | 1011 |
|
|
2020
Q3 | $1.15M | Buy |
20,952
+1,246
| +6% | +$67.1K | 0.01% | 966 |
|
|
2020
Q2 | $1.13M | Buy |
19,706
+1,826
| +10% | +$99.4K | 0.01% | 982 |
|
|
2020
Q1 | $718K | Hold |
17,880
| – | – | 0.01% | 1041 |
|
|
2019
Q4 | $707K | Sell |
17,880
-2,826
| -14% | -$49.6K | 0.01% | 1269 |
|
|
2019
Q3 | $140K | Hold |
20,706
| – | – | ﹤0.01% | 2142 |
|
|
2019
Q2 | $193K | Buy |
20,706
+8,314
| +67% | +$96.2K | ﹤0.01% | 2047 |
|
|
2019
Q1 | $172K | Hold |
12,392
| – | – | ﹤0.01% | 2052 |
|
|
2018
Q4 | $135K | Hold |
12,392
| – | – | ﹤0.01% | 2137 |
|
|
2018
Q3 | $157K | Hold |
12,392
| – | – | ﹤0.01% | 2223 |
|
|
2018
Q2 | $163K | Hold |
12,392
| – | – | ﹤0.01% | 2015 |
|
|
2018
Q1 | $169K | Buy |
+12,392
| New | +$128K | ﹤0.01% | 1979 |
|
Other funds holding CCXI
MetLife Investment Management's CCXI Position: Q4 2022 in Review
MetLife Investment Management sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 33,135 shares — an estimated $1.71M sold.
MetLife Investment Management first reported a position in CCXI in Q1 2018 and held it in 19 quarters. The position peaked at $1.71M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- MetLife Investment Management reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- MetLife Investment Management sold 33,135 ChemoCentryx, Inc. shares in Q4 2022, an estimated $1.71M.
- MetLife Investment Management first reported a position in ChemoCentryx, Inc. in Q1 2018 and held it in 19 quarters.
- MetLife Investment Management's ChemoCentryx, Inc. position peaked at $1.71M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on MetLife Investment Management's 13F filing for Q4 2022, filed 15 Feb 2023.